Supernus Pharmaceuticals traded at $49.91 this Friday March 13th, decreasing $0.55 or 1.09 percent since the previous trading session. Looking back, over the last four weeks, Supernus Pharmaceuticals lost 3.31 percent. Over the last 12 months, its price rose by 59.66 percent. Looking ahead, we forecast Supernus Pharmaceuticals to be priced at 48.40 by the end of this quarter and at 44.15 in one year, according to Trading Economics global macro models projections and analysts expectations.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.